Characterizing Subclinical ASCVD in Childhood Cancer Survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study uses advanced cardiovascular phenotyping in adult survivors enrolled in the St. Jude Lifetime Cohort to characterize subclinical ASCVD after cancer treatment. Participants undergo coronary artery calcium scoring, carotid ultrasound, lipoprotein(a) measurement, and noninvasive vascular function tests, with a control group undergoing identical assessments. The goal is to identify prevalent subclinical abnormalities and inform survivor-specific prevention strategies. The cross-sectional analysis will compare survivors with controls and explore associations by treatment exposure such as platinum chemotherapy or chest/neck radiation. A longitudinal follow-up plan exists to track incident ASCVD events over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- SJLIFE Survivor or Control

* Age ≥18 years
* Enrolled in the St. Jude Lifetime Cohort (SJLIFE)
* Participant or legal guardian/representative is able and willing to give informed consent.

SJLIFE Survivor only

* Participant has been treated with at least one of the following cancer therapies:

platinum chemotherapy, neck radiation exposure of at least 1000 centigray (cGy), or chest radiation exposure of at least 1000 cGy (with potential exposure to the heart).

Exclusion Criteria:

SJLIFE Survivor or Control

* Previous stroke or intervention for severe carotid arterial disease including carotid endarterectomy or carotid angioplasty and stent placement.
* Previous myocardial infarction or intervention for severe cardiovascular disease including Coronary Artery Bypass Graft (CABG), coronary stent placement or coronary angioplasty.
* History of aortic valve replacement
* Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Control Only

* First degree relative of SJLIFE Survivor
* History of cancer

Where it's running

• St. Jude Children's Research Hospital
  Memphis, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Stephanie B Dixon, MD, MPH — St. Jude Children's Research Hospital
• Study coordinator: Stephanie B Dixon, MD, MPH
• Email: referralinfo@stjude.org
• Phone: 888-226-4343

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HRS9531 for atherosclerotic cardiovascular disease

  This study tests whether HRS9531, compared with placebo, can reduce major adverse cardiovascular events in people with ASCVD.

  Recruiting Phase 3 Fujian Shengdi Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07551492

• Long-term use of inclisiran, evolocumab, and alirocumab in real-world care

  This study tests whether people with high cholesterol medications stick with their PCSK9 inhibitors and inclisiran over the long term in everyday clinical practice.

  Recruiting Novartis · Basel · NCT07543731

• Targeted lipid optimization program to improve LDL-C control in adults with ASCVD

  This program will test whether a targeted education-based lipid optimization program helps adults with ASCVD and high LDL-C reach recommended LDL-C targets better than usual care.

  Recruiting Phase 4 Novartis · Abu Dhabi · NCT07034690

• Using a genetic blood-pressure risk score to guide care for adults with high blood pressure

  This trial will test whether giving adults aged 18–55 with hypertension and poor cardiovascular health their genetic risk score for systolic blood pressure plus structured genomic counseling helps them lower blood pressure and improve healthy habits over 12 months.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT06962488

• Lipoprotein(a) levels in adults with atherosclerotic cardiovascular disease in Russia

  We will measure Lipoprotein(a) levels in adults with atherosclerotic cardiovascular disease in Russia and their relatives to see how common high levels are and whether they link to higher heart and stroke risk.

  Recruiting at 20 sites Novartis · Chelyabinsk and 19 other locations · NCT06858332

• Testing UDP-003 for safety and effectiveness in healthy individuals and patients with heart conditions

  This study is testing a new drug called UDP-003 to see if it's safe and effective for both healthy people and those with heart conditions, specifically looking at its ability to reduce plaque buildup in the arteries.

  Recruiting Early Phase 1 Cyclarity Therapeutics, Inc. · Adelaide, South Australia and 2 other locations · NCT06813339

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.